Case Control Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Mar 28, 2020; 26(12): 1329-1339
Published online Mar 28, 2020. doi: 10.3748/wjg.v26.i12.1329
Table 1 Candidate single-nucleotide polymorphisms selected from whole-exome sequencing of 8 Polygonum multiflorum-induced liver injury patients and 8 healthy controls
SNP IDChromosomeGeneNumber of PM-DILI patients with candidate SNPNumber of healthy controls with candidate SNP
rs10425972UGT1A860
rs379595832DRC163
rs1116868066HLA-A50
rs22311196HLA-A80
rs113690336HLA-A60
rs11566240136HLA-A60
rs11716297936HLA-A52
rs105951636HLA-A50
rs105034126HLA-B50
rs10553486HLA-B50
rs230865536HLA-B60
rs105045816HLA-B50
rs105148816HLA-B60
rs2020470446HLA-DRB140
rs1115348756HLA-DRB153
rs782461376HLA-DRB170
rs230876836HLA-DRB150
rs179993138NAT240
rs574793322PRODH73
Table 2 Demographic and clinical features of Polygonum multiflorum-induced liver injury patients and other drug-induced liver injury patients
CharacteristicsPM-DILI (n = 73)Other-DILI (n = 118)P
Mean age, yr47.7 ± 15.852.3 ± 14.20.045
Female, n (%)56 (76.7)74 (62.7)0.044
BMI23.6 ± 3.224.0 ± 3.70.447
Medication time1, d30 (45)30 (60.8)0.097
ALT (U/L)1105.0 ± 679.9626.3 ± 670.1< 0.001
AST (U/L), n797.7 ± 557.3 (65)485.6 ± 596.5 (118)0.001
ALP (U/L), n148.5 ± 58.4 (59)160.5 ± 212.3 (105)0.673
TBil (mg/dL), n112.9 ± 107.2 (61)76.9 ± 92.5 (99)0.026
Injury typen = 59n = 1050.917
Hepatocellular5782
Cholestatic112
Mixed111
RUCAM score0.319
3-5 (Possible)720
6-8 (Probable)5382
≥ 9 (Highly probable)1316
Table 3 Association between the 8 single-nucleotide polymorphisms and Polygonum multiflorum-induced liver injury
SNP IDChromose (Gene)Minor alleleMinor allele frequency (%)
PM-DILI vs control
PM-DILI vs Other-DILI
PM-DILI (n = 73)Other-DILI (n = 118)Control (n = 191)P valueOR (95%CI)P valueOR (95%CI)
rs10553486 (HLA-B)G42.5%13.6%8.6%1.72 × 10-19a13.62 (7.16-25.9)1.84 × 10-10a10.06 (5.06-20)
rs2020470446 (HLA-DRB1)C22.9%17.5%8.1%4.64 × 10-6a4.1 (2.25-7.47)0.2121.53 (0.84-2.76)
rs1116868066 (HLA-A)T27.2%27.6%11.6%1.72 × 10-5a3.96 (2.21-7.1)0.9370.97 (0.53-1.77)
rs22311196 (HLA-A)A26.0%24.4%36.8%0.0200.57 (0.36-0.90)0.7141.11 (0.66-1.85)
rs1115348756 (HLA-DRB1)A29.6%32.0%20.1%0.0221.64 (1.06-2.55)0.6220.89 (0.57-1.40)
rs10425972 (UGT1A8)G42.1%44.0%51.0%0.0710.71 (0.48-1.04)0.7230.93 (0.61-1.41)
rs782461376 (HLA-DRB1)T29.5%31.6%22.5%0.0951.45 (0.94-2.25)0.6560.9 (0.57-1.43)
rs574793322 (PRODH)T13.6%16.7%10.2%0.2791.35 (0.77-2.39)0.4240.8 (0.45-1.42)
Table 4 Biochemical characteristics between patients with the rs1055348 G allele and those without the rs1055348 G allele
VariablesPM-DILI
Other-DILI
With the rs1055348 G allele (n = 58)Without the rs1055348 G allele (n = 15)P valueWith the rs1055348 G allele (n = 32)Without the rs1055348 G allele (n = 86)P value
Age, mean ± SD, yr46.7 ± 15.151.2 ± 16.20.31749.2 ± 14.453.4 ± 14.00.152
Female, n (%)42 (72.4)14 (93.3)0.16722 (68.8)52 (60.5)0.408
BMI23.7 ± 2.923.0 ± 3.00.40723.8 ± 3.024.0 ± 3.90.774
Medication time1, d30 (40.8)30 (22)0.53346.5 (63.5)30 (54)0.269
ALT (U/L)1234.8 ± 609.5603.2 ± 517.0< 0.0001936.7 ± 866.7510.8 ± 532.70.013
AST (U/L), n876.9 ± 537.8 (51)509.2 ± 507.6 (14)0.025712.8 ± 691.5 (32)401.0 ± 513.4 (86)0.009
ALP (U/L), n155.8 ± 59.8 (48)116.7 ± 40.0 (11)0.044140.3 ± 99.4 (28)167.8 ± 240.8 (77)0.559
TBil (mg/dL), n123.9 ± 110.5 (48)70.7 ± 84.9 (13)0.11385.7 ± 104.8 (29)73.3 ± 87.4 (70)0.547
Table 5 Performance of the rs1055348 G allele for HLA-B*35:01 in the Polygonum multiflorum-induced liver injury group (n = 73) and the other drug-induced liver injury group (n = 78)
GroupTPTNFPFNSensitivity (95%CI)Specificity (95%CI)PPV (95%CI)NPV (95%CI)κ (95%CI)
PM-DILI608420100.0 (94.0-100.0)97.7 (91.9-99.7)96.8 (88.8-99.6)100.0 (95.7-100.0)0.959 (0.879-1.000)
Other-DILI2820440100.0 (87.7-100.0)98.1 (95.1-99.5)87.5 (71.0-96.5)100.0 (98.2-100.0)0.911 (0.825-0.996)